Stopped: Bankruptcy of Drug manufacturer: Drug not available
Background: * Idiopathic CD4 lymphocytopenia (ICL) is a condition in which patients have low levels of T cells, a type of white blood cell that helps fight infection. Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells. CYT107, however, has not been used in people with ICL. Objectives: * To determine the safety of CYT107 in people with ICL. * To determine whether CYT107 will increase the number and function of T cells in people with ICL. Eligibility: * Patients 18 years of age and older diagnosed with ICL and who are at risk of becoming sick because of this condition are eligible for this study. In addition, patients must not be pregnant, or have other illnesses that would cause low CD4 T cell counts, such as human immunodeficiency virus (HIV) or human T-lymphotrophic virus (HTLV) infection. Design: * The initial screening visit will include the following examinations and tests: * A complete physical exam and medical history * Blood analysis, including CD4 T cell count; complete blood count and additional blood tests to determine clotting ability and blood composition; thyroid, liver, kidney, and pancreatic function tests; HIV and HTLV tests; and tests for anti-IL-7 antibodies that block normal IL-7 activity * Routine urine test * Urine or blood pregnancy test for women * Chest X-ray * Electrocardiogram * Spleen ultrasound. * The baseline visit will include blood tests to determine levels of each of the major types of antibodies, a test of genetic background, and more detailed CD4 and protein analysis. In addition, leukapheresis (a procedure to collect large numbers of immune cells without red blood cells) will be done. Participants will also have the option of having colon and lymph node biopsies. * The schedule will be as follows: * Weeks 1, 2, and 3 (Cycle 1): Three weekly IL-7 dosing visits. * Weeks 5, 8, and 12: Follow-up visits. * Weeks 24, 25, and 26 (Cycle 2): Three more weekly IL-7 dosing visits. * Weeks 28, 31, and 35: Follow-up visits. * Week 48: End of study visit. * Tests conducted before getting IL-7 will be repeated during the IL-7 cycles and follow-up visits to compare with earlier values. Optional colon and lymph node biopsies done at baseline will be repeated 1 6 weeks prior to Cycle 2 and 1 6 weeks prior to Week 48.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Adverse Events and Toxicities Associated With CYT107.
Timeframe: 48 weeks per patient with a 3-4 year enrollment period